Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial

The Journal of Clinical Endocrinology and Metabolism
Aliya A KhanZeba A Syed

Abstract

Primary hyperparathyroidism (PHPT) is often associated with reduced bone mineral density (BMD). A randomized, double-blind, placebo-controlled trial was conducted to determine whether alendronate (ALN), 10 mg daily, maintains or improves BMD in patients with PHPT. Eligible patients had asymptomatic PHPT and did not meet surgical guidelines or refused surgery. Forty-four patients randomized to placebo or active treatment arms were stratified for gender. At 12 months, patients taking placebo crossed over to active treatment. All patients were on active treatment in yr 2. The primary outcome index, BMD, at the lumbar spine (LS), femoral neck, total hip, and distal one third radius was measured every 6 months by dual-energy x-ray absorptiometry. Calcium, phosphorous, PTH, bone-specific alkaline phosphatase (BSAP) activity, urinary calcium, and urinary N-telopeptide (NTX) excretion were monitored every 3 months. Treatment with alendronate over 2 yr was associated with a significant (6.85%; micro(d) = 0.052; +/-0.94% se; P < 0.001) increase in LS BMD in comparison with baseline. Total hip BMD increased significantly at 12 months with alendronate by 4.01% (micro(d) = 0.027; +/-0.77% se; P < 0.001) from baseline and remained stable ove...Continue Reading

Citations

Aug 9, 2012·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·I BaxterN Peel
May 14, 2011·Calcified Tissue International·Maurizio RossiniSilvano Adami
Nov 8, 2012·Langenbeck's Archives of Surgery·Lars RolighedPeer Christiansen
Jul 19, 2012·Wiener medizinische Wochenschrift·Katharina Kerschan-Schindl
Aug 19, 2006·Current Treatment Options in Oncology·Lindi H VanderWalde, Philip I Haigh
Mar 14, 2014·The Lancet. Diabetes & Endocrinology·David P MacfarlaneGraham P Leese
Sep 8, 2006·Nature Clinical Practice. Endocrinology & Metabolism·Shonni J Silverberg, John P Bilezikian
Feb 23, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Neveen At Hamdy
Dec 23, 2011·The New England Journal of Medicine·Claudio Marcocci, Filomena Cetani
Mar 17, 2010·American Journal of Therapeutics·Melanie L Dillon, Lawrence A Frazee
Dec 21, 2004·Journal of Internal Medicine·J P BilezikianS J Silverberg
Jun 9, 2007·Seminars in Dialysis·Paul D Miller
Oct 2, 2012·Therapeutic Advances in Musculoskeletal Disease·Claudio MarcocciFilomena Cetani
May 28, 2009·The Journal of Clinical Endocrinology and Metabolism·Claudio MarcocciMunro Peacock
Oct 15, 2010·The Journal of Clinical Endocrinology and Metabolism·Munro PeacockDolores Shoback
May 5, 2011·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Hafsah Al-Azem, Aliya Khan
Apr 23, 2010·Clinical Medicine : Journal of the Royal College of Physicians of London·N J L Gittoes, M S Cooper
Jul 1, 2006·Women's Health·Aliya Khan, Zeba Syed
Sep 3, 2008·World Journal of Surgery·Lindi H VanderWaldePhilip I Haigh
Aug 6, 2011·Clinical and Experimental Nephrology·Hirotaka KomabaMasafumi Fukagawa
Nov 16, 2007·The American Journal of the Medical Sciences·Michelle M Shepard, Jeffrey W Smith
Oct 23, 2013·Seminars in Diagnostic Pathology·Adriana LukJagdish Butany
Feb 5, 2013·Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry·Aline G Costa, John P Bilezikian
Feb 5, 2013·Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry·Aliya A Khan
Feb 5, 2013·Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry·Shonni J SilverbergJohn P Bilezikian
Dec 1, 2012·La Revue de médecine interne·G MaruaniP Houillier
Feb 11, 2012·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Rebeca Reyes GarcíaUNKNOWN Grupo de Metabolismo Mineral de la Sociedad Espa˜nola de Endocrinología y Nutrición
Jan 10, 2012·Metabolism: Clinical and Experimental·Mirella P HageGhada El-Hajj Fuleihan
Oct 30, 2010·Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry·E Michael Lewiecki
Jul 15, 2009·Lancet·William D Fraser
Mar 14, 2007·Mayo Clinic Proceedings·Bryan FarfordThomas J Moraghan
Jan 3, 2008·Clinical Endocrinology·Leif Mosekilde
Nov 27, 2007·European Journal of Clinical Investigation·R P WüthrichJ P Bilezikian
Jul 27, 2007·Clinical Endocrinology·Radu MihaiGregory P Sadler
Aug 19, 2011·Clinical Endocrinology·David P MacfarlaneGraham P Leese
Oct 12, 2013·Clinical Endocrinology·Rachel K Crowley, Neil J Gittoes
May 30, 2006·Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry·Aliya A KhanUNKNOWN Canadian Panel of the International Society for Clinical Densitometry
Jun 24, 2015·European Journal of Endocrinology·Bruno Niederle, Jean-Louis Wémeau
Apr 18, 2015·Annales d'endocrinologie·David P MacfarlaneGraham P Leese

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.